OncoMatch/Clinical Trials/NCT06882057
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Is NCT06882057 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Blinatumomab and Reinduction-2 omission for acute lymphoblastic leukemia all.
Treatment: Blinatumomab · Reinduction-2 omission · Chemo-light Maintenance 2 — CCCG-ALL2025 LR-B-ALL plan is designed based on the CCCG-ALL2020 plan. This is a clinical trial using 14 days of blinatumomab (Blina-14) as early intensification after induction therapy and 2nd Blina-14 in consolidation therapy in all newly diagnosed provisional low-risk (LR) pediatric acute lymphoblastic leukemia (ALL) patients, regardless of measurable residual diseases (MRD) status. We will compare the efficacy of chemotherapy combined with Blina-14, comparing to CAT+ intensification or historical regimens. Patients with early remission in depth will receive chemo-light late intensification and maintenance therapy afterwards. Early complete remission in depth and maintenance reduction will be determined by next-generation sequencing (Ig-NGS MRD).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Excluded: ABL1 fusion
Philadelphia chromosome positive ALL (Ph-ALL)
Excluded: IGHM surface IgM positive
sIgM+
Disease stage
Required: Stage LOW RISK GROUP
Excluded: Stage I/HR B-ALL GROUP
Low risk group; I/HR B-ALL group [excluded]
Prior therapy
Cannot have received: glucocorticoid
Glucocorticoid treatment for ≥14 days within one month before enrollment
Cannot have received: ABL kinase inhibitor
ABL kinase inhibitors for > 7 days within one month before enrollment
Cannot have received: chemotherapy
Exception: except for emergency radiotherapy to relieve airway compression
any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Cannot have received: radiotherapy
Exception: except for emergency radiotherapy to relieve airway compression
any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify